Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology and Zumutor Biologics announced a clinical collaboration to evaluate ZM008 in combination with LOQTORZI in a Phase 1 trial targeting various solid tumors including colorectal, head and neck, and NSCLC. Under the supply agreement, Zumutor will sponsor the trial while Coherus provides LOQTORZI, allowing Coherus to gather clinical data and expand indications cost-efficiently.
Key figures
- Trial id
- NCT06451497
- Phase Of Trial
- Phase 1
- Patients enrolled
- up to 45
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.